Herpes Zoster Ophthalmicus Market Future Outlook: Patient-Centric Solutions
The global Herpes Zoster Ophthalmicus (HZO) market is set to expand significantly over the next decade, offering new opportunities for manufacturers and healthcare providers. Valued at USD 5.1 billion in 2025, the market is expected to reach USD 6.8 billion by 2035, registering a compound annual growth rate (CAGR) of 2.9%. This growth is fueled by increasing prevalence of varicella-zoster virus reactivation affecting ocular health, particularly among older adults and immunocompromised populations. The rising awareness of early diagnosis and timely intervention is driving demand for effective therapies. Clinicians are increasingly prioritizing preventive care and rapid treatment to avoid serious complications, such as vision loss, positioning the market for sustained growth across both developed and emerging regions. Addressing the Core Needs of Healthcare Providers Manufacturers seeking to capitalize on the HZO market can leverage the growing emphasis on patient-cen...